The effects of active hexose correlated compound (AHCC) on level of CD4+ and CD8+ in epithelial ovarian cancer patients receiving platinum based chemotherapy
Phase 2
- Conditions
- CD4 and CD8 level in ovarian cancer patients receiving platinum base chemotherapy
- Registration Number
- TCTR20141119001
- Lead Sponsor
- Ratchadapiseksompotch foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
- First line chemotherapy
- Age between 20-70 years
- No underlying disease such as HIV infection SLE, leukemia ( low immune )
- Liver function within normal limit
- Kidney function within normal limit
- No steroid used
Exclusion Criteria
- History of radiation before or at time of receiving chemotherapy
- ECOG performance status more than 2
- Bone marrow metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare CD4 & CD8 level between AHCC & placebo before CMT, after CMT course 1, 3 & 6 CD4 & CD8 level
- Secondary Outcome Measures
Name Time Method Compare bone marrow suppression, QOL between AHCC & placebo Before CMT & after CMT every course CBC, FACT-G,Compare side effect between AHCC & placebo Before CMT & after CMT every course Clinical